Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Illnait Zaragozí, María T ^a   Martínez Machín, Gerardo F ^a   Fernández Andreu, Carlos M ^a   Hagen, Ferry ^b   Boekhout, Teun ^b   Klaassen, Corné H W ^c   Meis, Jacques F ^c  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

^b CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT; FUNGAL DNA; MICROSATELLITE DNA;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL DETECTION; FUNGAL STRAIN; FUNGUS ISOLATION; GENOTYPE; MICROSATELLITE MARKER; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; RECURRENT INFECTION; SEROTYPE; BLOOD; CEREBROSPINAL FLUID; CLASSIFICATION; CUBA; DRUG EFFECT; FEMALE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOLECULAR EPIDEMIOLOGY; RECURRENT DISEASE; SPERM; URINE;

ANTIFUNGAL AGENTS; BLOOD; CEREBROSPINAL FLUID; CRYPTOCOCCUS NEOFORMANS; CUBA; DNA, FUNGAL; FEMALE; GENOTYPE; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MICROBIAL SENSITIVITY TESTS; MICROSATELLITE REPEATS; MOLECULAR EPIDEMIOLOGY; MYCOLOGICAL TYPING TECHNIQUES; RECURRENCE; SEMEN; URINE;

EID: 77957277084     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-289     Document Type: Article

References (29)

1. Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull 2005, 72:99-118. 10.1093/bmb/ldh043, 15838017.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009, 23:525-30. 10.1097/QAD.0b013e328322ffac, 19182676.
3. Spitzer ED, Spitzer SG, Freundlich LF, Casadevall A. Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet 1993, 341:595-596. 10.1016/0140-6736(93)90354-J, 8094831.
4. Casadevall A, Spitzer ED, Webb D, Rinaldi MG. Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole. Antimicrob Agents Chemother 1993, 37:1383-1386. 187974, 8328793.
5. Pfaller M, Zhang J, Messer S, Tumberland M, Mbidde E, Jessup C, Ghannoum M. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients. Diagn Microbiol Infect Dis 1998, 32:191-199. 10.1016/S0732-8893(98)00095-9, 9884835.
6. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O, . French Cryptococcosis Study Group Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One 2008, 3(8):e2870. 10.1371/journal.pone.0002870, 2483933, 18682846, French Cryptococcosis Study Group.
7. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291-322. 10.1086/649858, 20047480.
8. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, Kanyemba C, Jarvis JN, Jaffar S, Hosseinipour MC, Kamwendo D, van der Horst CM, Harrison TS. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010, 50:338-344. 10.1086/649861, 20038244.
9. Fusco-Almeida AM, Teruyuki-Matsumoto M, Baeza LC, Bellan de Oliveira R, Pizzirani-Kleiner AA, de Souza Carvalho-Melhem M, Mendes-Giannini MJS. Molecular typing and antifungal susceptibility of clinical sequential isolates of Cryptococcus neoformans from Sao Paulo State, Brazil. FEMS Yeast Res 2007, 7:152-164. 10.1111/j.1567-1364.2006.00128.x, 17311593.
10. Haynes KA, Sullivan DJ, Coleman DC, Clarke JC, Emilianus R, Atkinson C, Cann KJ. Involvement of multiple Cryptococcus neoformans strains in a single episode of cryptococcosis and reinfection with novel strains in recurrent infection demonstrated by random amplification of polymorphic DNA and DNA fingerprinting. J Clin Microbiol 1995, 33:99-102. 227888, 7699075.
11. Sullivan D, Haynes K, Moran G, Shanley D, Coleman D. Persistence, replacement, and microevolution of Cryptococcus neoformans strains in recurrent meningitis in AIDS patients. J Clin Microbiol 1996, 34:1739-1744. 229105, 8784580.
12. Illnait-Zaragozi MT, Martínez-Machín GF, Fernández-Andreu CM, Boekhout T, Meis JF, Klaassen CH. Microsatellite typing of clinical and environmental Cryptococcus neoformans var. grubii isolates from Cuba shows multiple genetic lineages. PLoS One 2010, 9;5(2):e9124.
13. Clinical and Laboratory Standards Institute Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA 2008, 3, Clinical and Laboratory Standards Institute.
14. Barreto de Oliveira MT, Boekhout T, Theelen B, Hagen F, Baroni FA, Lazera MS, Lengeler KB, Heitman J, Rivera IN, Paula CR. Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. J Clin Microbiol 2004, 42:1356-1359. 10.1128/JCM.42.3.1356-1359.2004, 356826, 15004118.
15. Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004, 48:201-205. 10.1016/j.diagmicrobio.2003.09.008, 15023430.
16. Messer SA, Moet GJ, Kirby J, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 2009, 47:1942-1946. 10.1128/JCM.02434-08, 2691076, 19386851.
17. Illnait-Zaragozi MT, Martínez FG, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008, 52:1580-1582. 10.1128/AAC.01384-07, 2292518, 18212095.
18. Lozano-Chiu M, Paetznick VL, Ghannoum MA, Rex JH. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodologies. J Clin Microbiol 1998, 36:2817-2822. 105070, 9738026.
19. Aller AI, Martin-Mazuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway WJ, Gutierrez MJ, Recio FJ, Espinel-Ingroff A. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000, 44:1544-1548. 10.1128/AAC.44.6.1544-1548.2000, 89910, 10817706.
20. Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, Kwon-Chung KJ. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother 1999, 43:856-861. 89217, 10103191.
21. Guinea J, Bouza E. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol 2008, 3:603-615. 10.2217/17460913.3.6.603, 19072177.
22. Thompson GR, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009, 53:309-311. 10.1128/AAC.01216-08, 2612192, 18955539.
23. Dannaoui E, Abdul M, Arpin M, Nguyen AM, Piens MA, Favel A, Lortholary O, Dromer F. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob Agents Chemother 2006, 50:2464-2470. 10.1128/AAC.01520-05, 1489793, 16801427.
24. Jain N, Wickes BL, Keller SM, Fu J, Casadevall A, Jain P, Ragan MA, Banerjee U, Fries BC. Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol 2005, 43:5733-5742. 10.1128/JCM.43.11.5733-5742.2005, 1287776, 16272511.
25. Litvintseva A P, Kestenbaum L, Vilgalys R, Mitchell TG. Comparative analysis of environmental and clinical populations of Cryptococcus neoformans. J Clin Microbiol 2005, 43:556-564. 10.1128/JCM.43.2.556-564.2005, 548066, 15695645.
26. Igreja RP, Dos Santos-Lazera M, Wanke B, Gutierrez-Galhardo MC, Kidd SE, Meyer W. Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian City, Rio de Janeiro. Med Mycol 2004, 42:229-238. 10.1080/13693780310001644743, 15283237.
27. Fries BC, Casadevall A. Serial isolates of Cryptococcus neoformans from patients with AIDS differ in virulence for mice. J Infect Dis 1998, 178:1761-1766. 10.1086/314521, 9815230.
28. Friese G, Discher T, Füssle R, Schmalreck A, Lohmeyer J. Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS 2001, 15:2344-2345. 10.1097/00002030-200111230-00026, 11698718.
29. Desnos-Ollivier M, Patel S, Spaulding AR, Charlier C, Garcia-Hermoso D, Nielsen K, Dromer F. Mixed infections and in vivo evolution in the human fungal pathogen Cryptococcus neoformans. mBio 1(1). pii: e00091-10, 2912664, 20689742.